Stevanato Group (STVN) AI Stock Analysis

• Market Cap: $6.63B
• Dividend Yield: 0.25%
• Average Volume (3M): 323.77K
• Price to Earnings (P/E): 49.2
• Beta (1Y): 0.60
• Revenue Growth: 2.84%
• EPS Growth: -11.34%
• Country: US
• Employees: 5,521
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.11
• Shares Outstanding: 49,604,650
• 10 Day Avg. Volume: 379,752
• 30 Day Avg. Volume: 323,767
• PEG Ratio: 0.00
• Price to Book (P/B): 4.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -31.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $25.67
• Price Target Upside: 6.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 74 Outperform
• Price Target: $27.00 ▲(12.03%Upside)

Stevanato Group receives a strong score driven by solid financial performance and positive technical indicators. While high valuations and challenges in specific segments present risks, the company's growth trajectory and recent operational improvements provide a positive outlook. The balanced score reflects the company's potential and the need for improvement in cash management and valuation.

Positive Factors

Market Demand

There is a significant pickup in new ready-to-fill line activity, indicating increased medium-term demand, which is beneficial for Stevanato.

Operational Performance

The accelerated capacity expansion gives STVN a unique opportunity to capture share in the sterile cartridge market.

Revenue Growth

BDS revenue grew by 11% year over year to €221M, coming in ahead of expectations.

Negative Factors

Free Cash Flow

In FY25, free cash flow is expected to be negative, but capex is expected to normalize in FY26 and turn free cash flow positive.

Profitability Guidance

Management reiterated its revenue outlook for the year, while slightly adjusting down its profitability guidance due to the gross impact of tariffs.

Valuation

With the stock at 19.5 times estimated 2025 EBITDA, analysts await a better entry point.

Stevanato Group Business Overview & Revenue Model

Company Description

Stevanato Group (STVN) is a leading global provider of integrated containment and delivery solutions for the pharmaceutical, biotechnology, and life sciences industries. The company specializes in the design, production, and distribution of glass vials, syringes, cartridges, and other high-quality products essential for drug containment and delivery. Stevanato Group operates across multiple sectors, including healthcare, diagnostics, and industrial applications, providing comprehensive solutions that meet the stringent regulatory standards and safety requirements of the industry.

How the Company Makes Money

Stevanato Group generates revenue primarily through the manufacturing and sale of its proprietary glass and plastic products, which are essential components for the pharmaceutical and biotechnology sectors. The company offers a wide range of solutions, including glass vials, syringes, cartridges, and customized plastic products, which are used for the containment and delivery of drugs. Revenue streams are bolstered by long-term contracts and partnerships with major pharmaceutical companies, which rely on Stevanato’s products for their drug manufacturing and delivery processes. Additionally, the company provides value-added services such as analytical testing and regulatory support, enhancing its revenue potential. Significant factors contributing to its earnings include its advanced manufacturing capabilities, strong intellectual property portfolio, and global distribution network, enabling it to effectively meet the needs of a diverse client base.

Stevanato Group Financial Statement Overview

Summary

Stevanato Group shows solid financial performance with consistent revenue growth and strong profitability. The balance sheet highlights stable financial health with conservative leverage, although there is room for enhancing returns. Cash flow analysis indicates strong operational cash generation but negative free cash flow due to high capital expenditures, reflecting a focus on growth.

Income Statement

Stevanato Group has demonstrated consistent revenue growth with a TTM (Trailing-Twelve-Months) increase from the previous year. Gross Profit Margin is strong at 27.18%, reflecting efficient cost management in production. Net Profit Margin stands at 11.16%, indicating solid profitability. EBIT and EBITDA margins are healthy, at 15.16% and 24.80%, respectively, signaling effective operational performance. The company shows a robust growth trajectory, with some room for improvement in net profit margins.

Balance Sheet

The company's Debt-to-Equity Ratio is 0.28, indicating a conservative leverage strategy, which reduces financial risk. Return on Equity (ROE) is 8.86%, reflecting moderate efficiency in using equity to generate profit. Equity Ratio is 60.91%, which is a healthy sign of financial stability and lower risk. Overall, the balance sheet shows solid stability with potential for improving returns.

Cash Flow

Operating Cash Flow to Net Income Ratio is 1.47, suggesting healthy cash generation relative to net income. However, the Free Cash Flow remains negative, indicating high capital expenditures possibly for growth, which affects short-term cash availability. Free Cash Flow to Net Income Ratio is negative, reflecting a need for better cash management despite good operational cash flow.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.12B	1.10B	1.09B	983.70M	843.90M	662.04M
	Gross Profit
305.87M	302.32M	339.89M	319.80M	265.40M	194.18M
	EBIT
170.48M	161.14M	200.72M	152.58M	128.12M	103.11M
	EBITDA
278.95M	247.80M	272.35M	256.40M	226.93M	156.38M
	Net Income Common Stockholders
125.48M	117.78M	145.63M	142.85M	134.32M	78.51M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
90.72M	98.27M	72.18M	256.65M	438.21M	157.12M
	Total Assets
2.32B	2.33B	2.07B	1.66B	1.42B	967.98M
	Total Debt
393.35M	428.97M	396.59M	218.37M	244.29M	363.01M
	Net Debt
302.63M	330.70M	326.99M	-10.37M	-166.75M	247.41M
	Total Liabilities
908.28M	924.43M	938.93M	663.79M	577.18M	657.84M
	Stockholders Equity
1.42B	1.40B	1.13B	995.90M	841.70M	310.50M
Cash Flow		Free Cash Flow
-98.62M	-157.79M	-336.72M	-139.83M	20.12M	59.65M
	Operating Cash Flow
184.02M	155.78M	105.21M	103.30M	133.30M	155.66M
	Investing Cash Flow
-278.81M	-310.21M	-421.22M	-243.00M	-96.40M	-96.09M
	Financing Cash Flow
606.00K	183.22M	158.03M	-44.50M	254.80M	-26.52M

Stevanato Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Positive. The current price of 24.1 is above the 20-day moving average (MA) of 23.27, above the 50-day MA of 22.46, and above the 200-day MA of 21.02, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 56.12 is Neutral, neither overbought nor oversold. The STOCH value of 71.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STVN.

Stevanato Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	76 Outperform	$5.49B	45.59	9.16%	―	8.24%	18.54%
STVN	74 Outperform	$6.63B	49.24	9.08%	0.25%	2.84%	-11.34%
ICUI	68 Neutral	$3.28B	―	-4.62%	―	7.19%	-56.19%
BLCO	59 Neutral	$4.31B	―	-5.56%	―	11.94%	-6.98%
TFX	58 Neutral	$5.19B	37.04	3.48%	1.16%	0.29%	-48.98%
RGEN	56 Neutral	$7.08B	―	-1.16%	―	4.88%	-196.93%
Sector *	54 Neutral	$5.25B	3.27	-44.35%	6.27%	16.79%	-0.10%